{
    "clinical_study": {
        "@rank": "144458", 
        "arm_group": [
            {
                "arm_group_label": "metastatic breast cancer"
            }, 
            {
                "arm_group_label": "metastatic colorectal cancer"
            }, 
            {
                "arm_group_label": "metastatic gynecological cancer"
            }
        ], 
        "biospec_descr": {
            "textblock": "Fresh tumor tissue"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "This is a feasibility study to look for genetic alterations in tissue and blood samples that\n      may be useful in determining what treatments may be useful in the patient's cancer care."
        }, 
        "brief_title": "Feasibility Study of Genomic Profiling Methods and Timing in Tumor Samples", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Colorectal Cancer", 
            "Breast Cancer", 
            "Gynecological Cancer", 
            "Metastatic", 
            "Eligible for Phase I or Phase II Study"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Colorectal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "As part of the study, patients will have archival tumor tissue collected, and have tumor\n      biopsies and blood samples taken. The samples will be tested for genetic alterations, and\n      the results will be discussed with the patient including potential treatments. If patients\n      agree, after they have received treatment for their cancer and their disease progresses, a\n      second biopsy procedure will be done."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u2265 18 years.\n\n          -  Histological or cytological proof of either metastatic breast, colorectal or\n             gynecological malignancy.\n\n          -  At least one biopsiable lesion deemed medically accessible and safe to biopsy.\n\n          -  Candidate for one or more phase I or II clinical trials at the time of study\n             enrollment or at a later time point.\n\n          -  Fulfills local institution's laboratory parameters for tumor biopsy.\n\n          -  Willingness and ability of patient to provide signed voluntary informed consent.\n\n        Exclusion Criteria:\n\n          -  Any condition that could interfere with a patient's ability to provide informed\n             consent such as dementia or severe cognitive impairment.\n\n          -  Any contraindication to undergoing a biopsy procedure."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "metastatic metastatic breast, colorectal or gynecological cancer"
            }
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01703585", 
            "org_study_id": "MATCH-001"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "genomic analysis", 
            "genome", 
            "tumor", 
            "tissue", 
            "archival", 
            "biopsy", 
            "core needle", 
            "fine needle", 
            "DNA", 
            "gene", 
            "expression", 
            "sequencing"
        ], 
        "lastchanged_date": "December 18, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Toronto", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "M5G 2M9"
                }, 
                "name": "Princess Margaret Cancer Centre"
            }, 
            "investigator": [
                {
                    "last_name": "Lillian Siu, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Bedard Philippe, MD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_groups": "3", 
        "official_title": "A Feasibility Study of Genomic Profiling Methods and Timing of Sample Collection to Evaluate Clonal Evolution and Tumor Heterogeneity", 
        "overall_contact": {
            "email": "celeste.yu@uhn.ca", 
            "last_name": "Celeste Yu, MSc", 
            "phone": "416-946-4501", 
            "phone_ext": "4277"
        }, 
        "overall_official": [
            {
                "affiliation": "Princess Margaret Cancer Centre", 
                "last_name": "Lillian Siu, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Princess Margaret Cancer Centre", 
                "last_name": "Bedard Philippe, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Ethics Review Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Patient recruitment for paired core and fine needle biopsy greater than or equal to 50% of those screened or approached.", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01703585"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The rate of acceptable tumor samples from fresh core needle biopsy samples/total number of fresh core needle biopsy samples greater than or equal to 90%", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "The rate of acceptable tumor samples from fresh fine needle biopsy samples/total number of fresh fine needle biopsy samples greater than or equal to 50%", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Sequenom or MiSeq/TSCAP and MiSeq/NGS", 
                "measure": "Successful analysis of fresh core needle biopsy samples and fresh fine needle biopsy samples greater than or equal to 50%", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Sequenom or MiSeq/TSCAP analysis from fresh core needle biopsy samples less than 4 weeks; sequenom or MiSeq/TSCAP analysis from fresh fine needle biopsy samples less than 8 weeks; MiSeq/NGS analysis from fresh core needle biopsy samples less than 8 weeks; MiSeq/NGS analysis from fresh fine needle biopsy samples less than 8 weeks", 
                "measure": "Analysis of fresh core needle biopsy samples and fresh fine needle biopsy samples from time from patient recruitment to final results, less than a defined period of time, in greater than or equal to 90%", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Actionable genomic result analysis of fresh core needle biopsy samples and fresh fine needle biopsy samples greater than or equal to 30%", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "University Health Network, Toronto", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Ontario Institute for Cancer Research", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Princess Margaret Hospital, Canada", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University Health Network, Toronto", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "December 2012"
    }
}